|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
102.66(B) |
Last
Volume: |
315,729 |
Avg
Vol: |
765,410 |
52
Week Range: |
$692.45 - $993.95 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
173,066 |
236,471 |
279,472 |
438,206 |
Total Sell Value |
$168,792,636 |
$226,505,895 |
$262,153,799 |
$373,147,368 |
Total People Sold |
8 |
14 |
16 |
18 |
Total Sell Transactions |
18 |
42 |
60 |
120 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bassler Bonnie L |
Director |
|
2022-12-08 |
4 |
AS |
$779.00 |
$169,822 |
D/D |
(218) |
1,082 |
|
4% |
|
Bassler Bonnie L |
Director |
|
2022-12-08 |
4 |
OE |
$380.95 |
$83,047 |
D/D |
218 |
1,300 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2022-12-02 |
4 |
AS |
$756.50 |
$461,564 |
D/D |
(610) |
28,744 |
|
8% |
|
Ryan Arthur F |
Director |
|
2022-12-01 |
4 |
AS |
$752.57 |
$75,817 |
D/D |
(100) |
19,282 |
|
9% |
|
Mccourt Marion |
EVP Commercial |
|
2022-12-01 |
4 |
AS |
$756.19 |
$831,809 |
D/D |
(1,100) |
19,644 |
|
9% |
|
Mccourt Marion |
EVP Commercial |
|
2022-12-01 |
4 |
OE |
$372.46 |
$409,706 |
D/D |
1,100 |
20,744 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2022-12-01 |
4 |
D |
$760.35 |
$1,437,062 |
D/D |
(1,890) |
29,354 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2022-12-01 |
4 |
OE |
$381.92 |
$954,800 |
D/D |
2,500 |
31,244 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2022-11-15 |
4 |
AS |
$718.60 |
$2,707,467 |
D/D |
(3,720) |
57,110 |
|
12% |
|
Murphy Andrew J |
EVP Research |
|
2022-11-14 |
4 |
D |
$746.00 |
$4,684,880 |
D/D |
(6,280) |
60,830 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2022-11-14 |
4 |
OE |
$179.13 |
$1,791,300 |
D/D |
10,000 |
67,110 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2022-11-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,360 |
57,110 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2022-11-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
330 |
52,465 |
|
- |
|
Brown Michael S |
Director |
|
2022-11-08 |
4 |
AS |
$748.49 |
$374,245 |
I/I |
(500) |
6,662 |
|
-0% |
|
Brown Michael S |
Director |
|
2022-11-08 |
4 |
AS |
$748.48 |
$3,016,946 |
D/D |
(3,995) |
1,082 |
|
-0% |
|
Brown Michael S |
Director |
|
2022-11-08 |
4 |
OE |
$374.12 |
$1,664,397 |
D/D |
3,995 |
3,313 |
|
- |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2022-11-07 |
4 |
S |
$742.79 |
$5,878,263 |
D/D |
(7,886) |
30,578 |
|
-1% |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2022-11-04 |
4 |
D |
$725.84 |
$18,954,586 |
D/D |
(26,114) |
38,464 |
|
- |
|
Van Plew Daniel P |
EVP & General Mgr, Industrial |
|
2022-11-04 |
4 |
OE |
$381.92 |
$12,985,280 |
D/D |
34,000 |
64,578 |
|
- |
|
Mccourt Marion |
EVP Commercial |
|
2022-11-04 |
4 |
S |
$727.82 |
$727,820 |
D/D |
(1,000) |
19,644 |
|
-3% |
|
Mccourt Marion |
EVP Commercial |
|
2022-11-04 |
4 |
OE |
$372.46 |
$372,460 |
D/D |
1,000 |
20,644 |
|
- |
|
Ryan Arthur F |
Director |
|
2022-11-01 |
4 |
AS |
$750.00 |
$75,589 |
D/D |
(100) |
19,382 |
|
0% |
|
Landry Robert E |
EVP Finance CFO |
|
2022-11-01 |
4 |
AS |
$750.00 |
$365,386 |
D/D |
(482) |
28,744 |
|
0% |
|
Mccourt Marion |
EVP Commercial |
|
2022-11-01 |
4 |
AS |
$750.00 |
$825,000 |
D/D |
(1,100) |
19,644 |
|
0% |
|
Mccourt Marion |
EVP Commercial |
|
2022-11-01 |
4 |
OE |
$372.46 |
$409,706 |
D/D |
1,100 |
20,744 |
|
- |
|
1367 Records found
|
|
Page 11 of 55 |
|
|